KKR来上海募集人民币了

Core Viewpoint - KKR has successfully launched its first onshore RMB fund in Shanghai, marking a significant milestone in its commitment to the Chinese market and reflecting the growing interest of foreign capital in Chinese assets [3][4][7]. Fund Details - The fund, named Kaide Shipu (Shanghai) Private Investment Fund Partnership (Limited Partnership), was established in June 2025 and registered in Shanghai's Pudong district, focusing on equity investments in RMB [5][6]. - The fund management is handled by Kaide Private Fund Management (Shanghai) Co., Ltd., backed by KKR, with notable limited partners including Ping An Capital and the TPC family office from Singapore [6][7]. Market Context - The A-share market has recently surpassed a total market capitalization of 100 trillion yuan for the first time, indicating a robust market environment that is attracting foreign investment [3][14]. - There is a notable influx of foreign private equity firms establishing operations in China, with several new fund management companies registered in 2023, highlighting the increasing appeal of the Chinese market [13]. KKR's Investment Strategy - KKR's investment strategy focuses on mature industries with stable competitive landscapes, aiming for companies with strong pricing power and potential for operational efficiency improvements [10]. - Despite a decrease in the number of investments in recent years due to pricing discrepancies between buyers and sellers, KKR believes that there are more acquisition opportunities now than in the past [10]. Recent Acquisitions - KKR is actively pursuing acquisitions in China, including the recent approval for the acquisition of shares in Yuanjing International, associated with the popular Da Yao soda brand [10][11]. - The firm is also competing in the bidding for Starbucks' business in China, indicating its aggressive stance in the market [10]. Foreign Investment Sentiment - There is a growing recognition among global investors that the best assets are in China, with a significant increase in interest in Chinese technology companies and innovative pharmaceuticals [14][15]. - The sentiment reflects a broader trend of foreign capital seeking to capitalize on China's vast consumer market and supply chain capabilities [15].